Ozempic on TikTok: separating the science from the hype

What did @by.irenesainz actually say?

Honestly, this is where the fact-check hits a wall immediately. The transcript provided for this video is largely incoherent, reading like a garbled auto-transcription of a non-English speaker recorded in poor audio conditions. Lines like "go from a smallerk side to a smallerk side" and "we are not even a repcheting in what we call" are not recoverable claims. They are transcription noise, not science.

What we can infer from context is meaningful, though. The hashtags, caption, and creator handle point to a Spanish-language educational video about semaglutide (Ozempic). The hashtags include #biologyclass and #divulgacioncientifica, suggesting the creator intended to explain how Ozempic works at a biological level. References to food, meals, and appetite suggest the video likely touched on GLP-1's role in satiety and eating behavior, which is the core mechanism people actually want to understand.

Because the transcript is unusable for direct quoting, this fact-check will assess the claims most commonly made in Spanish-language Ozempic explainer videos and flag what gets right, wrong, or oversimplified.

Does the science back up typical Ozempic explainer claims?

The core biology of semaglutide is well-established, and most good-faith explainers get the basics right. Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone released in your gut after eating, and it does several things: it stimulates insulin release, suppresses glucagon, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite. That last part is why people eat less on it.

The clinical evidence is substantial. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found adults on 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major cardiovascular events in people with obesity and established cardiovascular disease but without diabetes. These are not marginal findings. They are large, well-powered randomized controlled trials.

Where explainer videos often stumble is implying Ozempic is a passive fix. It is not. Weight loss in trials occurred alongside lifestyle intervention. The drug changes your appetite signaling. It does not change your habits automatically.

What did they get wrong (or right)?

Because the transcript is unreadable, assigning precise errors is impossible without viewing the original video. However, the most common errors in this content category are worth naming directly.

• Overstating the mechanism: Many creators say semaglutide "tricks your brain into thinking you are full." That is a simplification. It activates GLP-1 receptors in the arcuate nucleus and other hypothalamic regions, reducing orexigenic signaling. It is not a trick. It is pharmacology.
• Ignoring side effects: Nausea, vomiting, gastroparesis, and in rare cases pancreatitis are real. The FDA label includes a boxed warning for thyroid C-cell tumors based on rodent data. That does not mean every viewer will get cancer. It means you should talk to a provider, not a TikTok comment section.
• Implying anyone can just get it: Semaglutide for weight loss (Wegovy) is FDA-approved for adults with a BMI of 30 or greater, or 27 or greater with a weight-related condition. It is a regulated prescription medication. It requires clinical evaluation.

If @by.irenesainz explained the gut-brain axis clearly and noted the drug requires medical supervision, that would be credit well earned. Without a legible transcript, we cannot confirm or deny it.

What should you actually know?

Semaglutide works. The data is real and the effect sizes are clinically meaningful. But the TikTok information environment around Ozempic is full of people who got a prescription, lost weight, and now feel qualified to explain endocrinology. Feeling results is not the same as understanding mechanisms.

A few things worth knowing that often get left out of explainer videos. First, weight regain after stopping is well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within a year of stopping semaglutide. The drug manages a chronic condition. It does not cure it. Second, muscle loss during rapid weight loss is a real concern. Some researchers and clinicians are increasingly pairing GLP-1 agonists with resistance training protocols, though the evidence base for that combination is still developing. Third, compounded semaglutide is not the same as Ozempic or Wegovy. The FDA has stated clearly that compounded versions are not FDA-approved and quality cannot be guaranteed. Any content that implies otherwise is doing viewers a disservice.

If you are considering semaglutide, the right first step is a licensed provider, not a 60-second video, however well-intentioned.